Form 4: Solid Biosciences CMO Gabriel Brooks Reports Equity Transactions

Solid Biosciences Chief Medical Officer Gabriel Brooks reported the vesting of performance and restricted stock units, new option grants, and a tax-related stock sale.

Summary

• Gabriel Brooks, Chief Medical Officer of Solid Biosciences Inc. (SLDB), reported several equity transactions.
• On January 29, 2026, 58,847 Performance Stock Units (PSUs) vested and converted into common stock, following the achievement of a predetermined business objective.
• Also on January 29, 2026, Brooks was granted 207,450 employee stock options with an exercise price of $6.60 and 103,750 Restricted Stock Units (RSUs).
• On January 31, 2026, 28,225 RSUs from a January 31, 2025 grant vested and converted into common stock.
• On February 2, 2026, Brooks sold 28,335 shares of common stock at a weighted average price of $6.4369 per share to cover withholding taxes related to the vesting of previously granted PSUs. This was a non-discretionary "sell-to-cover" transaction.
• Following these transactions, Brooks beneficially owns 96,708 shares of common stock, 207,450 employee stock options, and 84,675 Restricted Stock Units.
• The reported common stock holdings also include 4,152 shares acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 28, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting the achievement of performance milestones and continued executive incentive through new equity grants, while the stock sale was non-discretionary for tax purposes.

Positives

• Vesting of 58,847 Performance Stock Units (PSUs) on January 29, 2026, indicating the achievement of a predetermined business objective.
• Grant of 207,450 new employee stock options on January 29, 2026, demonstrating continued incentive for management.
• Grant of 103,750 new Restricted Stock Units (RSUs) on January 29, 2026, further aligning management interests with shareholders.
• Vesting of 28,225 Restricted Stock Units (RSUs) on January 31, 2026, from a prior grant.

Negatives

• Sale of 28,335 shares of common stock on February 2, 2026, reducing direct share ownership, although this was a non-discretionary tax-related sale.

Future Outlook

The filing details future vesting schedules for newly granted employee stock options and Restricted Stock Units, with options vesting over four years (25% on first anniversary, then monthly) and RSUs vesting over four years (25% on each anniversary).

Management Comments

• The sale of common stock was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024, effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

Industry Context

StockSavvy.ai notes that equity compensation, including PSUs, RSUs, and stock options, is a standard practice in the biotechnology industry to attract, retain, and incentivize key executives like Chief Medical Officers. The achievement of performance milestones for PSUs is a positive indicator of progress on non-financial business objectives, common in early-stage biotech where clinical or regulatory milestones are critical.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The vesting of performance-based awards indicates progress on company objectives, potentially aligning executive interests with shareholder value. The non-discretionary sale for taxes is a routine event and not indicative of a lack of confidence.
• Employees: The grants of stock options and RSUs to the Chief Medical Officer demonstrate the company's commitment to incentivizing key personnel.

Next Steps

• Continued vesting of employee stock options granted on January 29, 2026, with 25% vesting on the first anniversary and 2.0833% monthly thereafter until the fourth anniversary.
• Continued vesting of Restricted Stock Units granted on January 29, 2026, with 25% vesting on each anniversary until the fourth anniversary.
• Continued vesting of Restricted Stock Units granted on January 31, 2025, with 25% vesting on each anniversary until the fourth anniversary.
• Future achievement of remaining three independent performance milestones for PSUs, subject to Board certification and continued service.

Key Dates

Recommendation

The filing details routine executive compensation events, including the vesting of performance-based awards and new equity grants, alongside a non-discretionary tax-related stock sale. These transactions do not provide new fundamental information to warrant a change in investment thesis, suggesting a 'hold' recommendation for existing investors.

Keywords

Solid Biosciences, SLDB, Gabriel Brooks, Form 4, Insider Trading, Equity Compensation, Stock Options, Restricted Stock Units, Performance Stock Units, Biotechnology, Executive Compensation